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Abstract 
Background: Estimated plasma volume status (ePVS) has diagnostic and prognostic value in patients with heart 
failure (HF). However, it remains unclear which congestion markers (i.e., biological, imaging and hemodynamic 
markers) are preferentially associated with ePVS. In addition, there is evidence of sex differences in both the 
hematopoietic process and myocardial structure/function.  
Method and results: Patients with significant dyspnea (NYHA≥2) underwent echocardiography and lung ultrasound 
within four hours prior to cardiac catheterization. Patients were divided according to tertiles based on sex-specific 
ePVS thresholds calculated from hemoglobin and hematocrit measurements using Duarte’s formula.  
Among the 78 included patients (median age 74.5 years; males 69.2%; HF 48.7%), median ePVS was 4.1 
(percentile25-75=3.7-4.9) ml/g in males (N=54) and 4.8 (4.4-5.3) ml/g in females (N=24). Patients with the highest 
ePVS had more frequently HF, higher NT-proBNP, larger left atrial volume and higher E/e’ (all p-values<0.05), but 
no difference in inferior vena cava diameter or pulmonary congestion assessed by lung ultrasound (all p-values>0.10). 
In multivariable analysis, higher E/e’ and lower diastolic blood pressure were significantly associated with increased 
ePVS. The association between ePVS and congestion variables was not sex-dependent except for left ventricular end-
diastolic pressure, which was only correlated with ePVS in females (Spearman Rho=0.53, p<0.01 in females and 
Spearman Rho=-0.04, p=0.76 in males; pinteraction=0.08). 
Conclusion: ePVS is associated with E/e’ regardless of sex, while only associated with invasively measured left 
ventricular end-diastolic pressure in females. These results suggest that ePVS is preferably associated with left-sided 
hemodynamic markers of congestion. 
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Introduction 
Plasma volume is a marker of volume overload and is linked to the regulation between interstitial and intravascular 
spaces 1, 2. Estimated plasma volume status (ePVS) derived from hemoglobin and hematocrit has been repeatedly 
reported to be associated with clinical outcomes in patients with acute or chronic heart failure (HF) 3-6. Previous 
reports showed only a moderate association between ePVS using various equations and radiotracer-based quantitative 
plasma volume measurements 4, 7, 8. However, the correlation between PV estimated from hemoglobin/hematocrit and 
measured PV by 125I-human serum albumin in diabetic patients was recently showed to be acceptable (concordance 
index 0.6, P<0.01) 9. There are only sparse data however regarding the association of ePVS with clinical, biological 
and echocardiographic congestion as well as with invasive hemodynamic parameters 5, 6, 10-12. Whether ePVS is more 
closely associated with pulmonary or systemic congestion markers has yet to be ascertained.  
In addition, current evidence suggests that there are underlying sex differences in hematopoiesis 13, myocardial 
structure and function 14, 15. These sex differences may have a substantial impact on the appropriate ePVS thresholds. 
However, whether the association between congestion markers and ePVS is sex-dependent remains to be established.  
The present study aimed to investigate 1) the association of ePVS with clinical, biological, echocardiographic 
as well as invasive hemodynamic congestion variables and 2) whether these associations are sex-dependent. 
 
Methods 
Patient Population 
This study prospectively included 81 patients with significant dyspnea (NYHA≥II) who underwent a coronary 
angiography with left heart catheterization (LHC) between May 2016 and July 2017 16. Seventy-eight patients who 
had available hemoglobin/hematocrit data were included in this subsequent analysis. Exclusion criteria were: mitral 
stenosis, known pulmonary fibrosis, pneumonia, active lung cancer and history of recent chest trauma. Demographic 
characteristics, comorbidities and biological profiles were obtained from review of medical records. HF was 
diagnosed according to the ESC guidelines 17. Estimated glomerular filtration rate (eGFR) was calculated by the 
Chronic Kidney Disease Epidemiology Collaboration formula 18. The study protocol was approved by the local ethics 
committee (authorization number: 2014-A01331-456).  
 
Transthoracic Echocardiography 
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All patients underwent a standard echocardiography using a Vivid S6, E7 or E9 ultrasound system (General Electric 
Healthcare, Horten, Norway). Images were recorded on a remote station for off-line analysis using a dedicated 
software (EchoPAC PC, version BT 13, General Electric Healthcare, Horten, Norway). Interpretation was blinded for 
clinical and hemodynamic data. Left ventricular ejection fraction (LVEF) was measured using the biplane Simpson’s 
method 19. Diastolic function was assessed from the pattern of mitral inflow by pulsed-wave Doppler. Mitral annular 
early diastolic velocity (e’) was assessed at the septal and lateral sites of the mitral annulus using tissue Doppler 
imaging. E/A ratio, e’ mean and E/e’ mean ratio were calculated. Inferior vena cava (IVC), tricuspid annulus plane 
systolic excursion and left atrial volume (LAV) were obtained as recommended 19. Pulmonary arterial systolic 
pressure was estimated using tricuspid velocity and inferior vena cava compliance and diameter 19. Right ventricular 
(RV) function was assessed according to recent guidelines 19.  
 
Hemodynamic Data and Lung Ultrasonography 
LHC was performed within four hours following echocardiography. Prior to coronary angiography, transducers were 
calibrated, with a 0-level set at the mid-axillary line. The left ventricular end-diastolic pressure (LVEDP) was 
continuously recorded (25 mm/s) with a 5 French Judkin R4 catheter (ICU Medical, San Clemente, CA, USA) placed 
at the mid-LV cavity. Waveform analysis was blinded from clinical and echocardiographic data. LVEDP was 
calculated as the mean value of 4 consecutive heart cycles. 
Lung ultrasound was performed immediately before echocardiography with patients in supine or near-to-
supine position, as previously described 20. Loops were stored on a remote station for off-line analysis using the same 
tools as those used for echocardiography. For each lung ultrasound zone, the number of B-lines was quantified from 0 
to 10, with resulting LUS scoring ranging from 0 to 80 (8-zone method). An excellent reproducibility of 
measurements, performed by experienced cardiologists, has previously been reported in this population 16.  
 
Estimated Plasma Volume Status 
ePVS was calculated from the Strauss-derived Duarte formula using hematocrit and hemoglobin values 3 as follows: 
ePVS (mL/g)=100 × (1-hematocrit)  ⁄  hemoglobin in g/dL 
The Hakim formula was also used for calculating plasma volume estimation derived from hematocrit and dry 
body weight using the following equations 21: 
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Actual plasma volume=(1 - hematocrit) × (a + b × body weight in kg)  
Ideal plasma volume=c × body weight in kg 
(males: a=1530, b=41.0, c=39; females; a=864, b=47.9, c=40),  
ePVS=[(actual plasma volume - ideal plasma volume)/ideal plasma volume]×100. 
 
Statistical Analysis 
Continuous data are expressed as median (25 and 75 percentile) and categorical data as numbers (%). Patients were 
divided into three groups according to sex-specific ePVS tertiles [median (IQR) = 4.07 (3.73-4.93) ml/g in males and 
4.76 (4.37-5.27) ml/g in females]. Group differences were assessed using Kruskal-Wallis tests for continuous 
variables and χ² tests or Fisher’s exact test for categorical variables. Unadjusted correlations were expressed using 
Spearman’s correlation coefficients.  
Linear regression analyses were performed to evaluate the association of ePVS with clinical, biological, 
echocardiographic and invasive hemodynamic variables. All variables with a P<0.10 in univariable analysis were used 
as candidate variables in the multivariable model prior to backward selection procedures. An interaction test was 
performed to determine whether the associations between ePVS and congestion markers are sex-dependent.  
Statistical analyses were performed using R version 3.4.0 (R Development Core Team, Vienna, Austria). A 
two-sided p-value <0.05 for associations and p < 0.10 for interactions were considered statistically significant. 
 
Results  
Baseline Characteristics according to Renin and Aldosterone Levels 
Among the 78 patients included in this study, 54% were male, median age was 74.5 (67.0-80.0) years, one-fifth (21.8 
%) of the population had a BMI ≥30kg/m² and a half (48.7%) had HF and coronary artery (Table 1).  
Patients in the highest ePVS tertiles had more frequently HF, higher N-terminal pro-B-type natriuretic peptide 
(NT-proBNP), LAV index, E/e’ and lower RV isovolumic acceleration compared to patients in the lowest ePVS 
tertiles (all p<0.05) (Table 1). In contrast, there was no significant difference in IVC, LVEDP and B-line counts 
across ePVS tertiles.  
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Clinical Determinants of Estimated Plasma Volume Status 
Univariable linear regression analysis showed that elderly age, female sex, lower BMI, diastolic BP, higher NT-
proBNP, larger LAV index and higher E/e’ were significantly associated with higher ePVS (Table 2). In multivariable 
linear regression models, only female sex, higher E/e’ and lower diastolic BP were significantly associated with higher 
ePVS (Table 2).  
Correlation between ePVS and congestion markers across heart rhythm and LVEF strata is shown in 
Supplementary table 1. ePVS significantly correlated with E/e’ only in patients with sinus rhythm, whereas similar 
correlations between ePVS and congestion marker were found across LVEF strata. 
 
Interplay between Sex, Estimated Plasma Volume Status and other Congestion Markers 
ePVS was found to be significantly correlated with NT-proBNP (rho=0.36, p=0.01), E/e’(rho=0.33, p<0.01) and LAV 
index (rho=0.31, p<0.01). Among congestion markers, only LVEDP was observed to have a sex-specific association 
with ePVS solely in females (rho=0.53, p<0.01 in females and rho=-0.04, p=0.76 in males; pinteraction=0.08) (Figure 1). 
Of note, LVEDP was not associated with higher ePVS in either univariable or multivariable analysis (Table 2). 
 
Estimated Plasma Volume Status Calculated by the Hakim formula 
Sex-specific ePVS tertiles derived from the Hakim formula were also applied in the present population [median 
(IQR)= -9.45 (-15.61 - 1.06) % in males and -7.29 (-10.01 - 4.02) % in females] (Supplementary table 2). Patients 
with the highest ePVS tertiles were older, had lower BMI and were less likely to have atrial fibrillation (all p-
value<0.05). However, there were no significant differences in biological, echocardiographic and invasive 
hemodynamic congestion markers across ePVS tertiles. 
Multivariable linear regression models showed that ePVS was only associated with BMI and diastolic BP 
(Supplementary table 3). 
 
Discussion 
The current study is the first to assess the association of ePVS with clinical, biological, echocardiographic and 
invasive hemodynamic congestion markers. Our main findings are that: 1) higher ePVS derived from the Duarte 
formula was significantly associated with higher E/e’ in multivariable analysis; 2) LVEDP was correlated with ePVS 
using the Duarte formula in females, while  not associated with ePVS in the overall population; 3) ePVS derived from 
the Hakim formula was not associated with usual congestion markers. The above results suggest that ePVS derived 
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from the Duarte formula may be an easily-accessible surrogate of measured markers of left-sided hemodynamic 
congestion in routine clinical practice. 
Estimated Plasma Volume Status – a left-sided congestion variable 
Our findings outline certain underlying features of plasma volume that have not been previously addressed. Among all 
patients included in our study, results showed that higher E/e’ was associated with a higher ePVS level, but not with 
B-lines or LVEDP. There is growing evidence linking pulmonary interstitial edema quantified by lung ultrasound and 
elevated invasive measurements of LV filling pressures 16, 22. In contrast, a recent meta-analysis emphasized the lack 
of diagnostic value of E/e’ ratio in predicting LV filling pressure 23. This being said, E/e’ is nevertheless a recognized 
congestion marker shown to be associated with clinical outcome in population-based or HF cohorts 24-26. Given that 
we did not identify a significant association between ePVS and IVC, our findings further suggest that ePVS is more 
likely a left-sided congestion marker. This premise is also supported by the biological findings presented herein: 
patients within the highest ePVS tertiles had higher NT-proBNP, which is also typically considered as a left-sided 
congestion marker 27, 28. This result is also in keeping with previous reports in patients with HF and reduced or 
preserved LVEF 3, 4, 29, 30. In addition, we observed a better correlation between ePVS and E/e’ in patients with sinus 
rhythm. It may be partly explained by the lack of predictive performance of Doppler echocardiography for LV 
pressures in patients with atrial fibrillation 19. 
The absence of a strong association between IVC and ePVS may be partly explained by the fact that over two-
thirds of the total blood volume resides in the venous circulation, which is relatively unaffected by changes in fluid 
volume given its high capacitance 31. Another noteworthy finding of the present study is the strong association 
between lower diastolic BP and increased ePVS. BP is an important modulator of the complex interaction between 
interstitial fluid and plasma volume1. This could provide some pathophysiological basis for decreased diastolic BP 
favoring intravascular volume retention, which would translate into higher ePVS. 
Sex Difference in the association of Estimated Plasma Volume Status with other markers of congestion 
LVEDP was observed herein to be positively correlated with ePVS in females but not in males. Women have been 
shown to be more prone to impaired LV diastolic reserve 14, 32. This may partly explain why a higher left volume load 
(as measured by ePVS) was better correlated with LVEDP since the left ventricle in women (particularly in older 
women) is unable to mitigate intravascular pressure. The same amount of volume could indeed translate into different 
pressure levels according to the intrinsic diastolic properties of the heart. Irrespectively, these findings suggest that 
increased ePVS may be a more relevant marker of cardiopulmonary congestion in females 33, 34. In contrast, there was 
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no sex-dependent interaction of ePVS with other congestion markers such as NT-proBNP and E/e’. Both congestion 
markers were reported to have sex-dependency 35-37, which may influence this sex-dependent interaction. The 
pathophysiological mechanism which may explain the sex-different association of ePVS with LVEDP needs to be 
further evaluated in future studies. Both clinical studies and animal studies would be interesting to refine our 
understanding of these differences in association between congestion variables. 
Clinical Perspectives 
Hemodynamic congestion can precede symptoms of congestion by several days. Plasma volume, estimated from 
hemoglobin/hematocrit using Duarte’s formula or hematocrit/body weight using the Hakim formula, could represent 
easy-to-use markers in routine clinical practice. In contrast, we observed no significant association between 
congestion markers and ePVS derived from the Hakim formula. This differential association could be related to the 
Hakim formula incorporating “dry” body weight. There is a complex interplay of congestion and cachexia in HF 
patients which may explain that PV estimated from Hakim formula becomes less effective in this clinical setting 38, 39. 
Importantly, previous reports showed moderate associations between ePVS derived from Duarte/Hakim formula and 
radiotracer-based quantitative plasma volume measurements which could explain variations of association between 
ePVS and other congestion markers. In contrast, Duarte-derived ePVS was significantly associated with E/e’ (in the 
whole population) and LVEDP (in females) in the current study (Figure 2). 
ePVS using Duarte's formula may be a useful integrative marker of left-sided hemodynamic congestion. Other 
congestion markers such as E/e’ and LVEDP often cannot be repeatedly measured especially in the context of 
ambulatory patients with HF 28. Therefore, PV estimated from Duarte formula could potentially become a useful 
congestion marker in the management of HF given its low cost and practicability. Large-scale multicenter studies are 
invariably needed to determine whether ePVS-guided treatment can improve clinical outcome in HF patients. 
Limitations  
First, this is a single-center cohort study; thus, there may be residual confounding and generalizability is not 
unequivocal. The moderate size of our cohort only yielded moderate statistical power. Second, we had no direct 
measurement of plasma volume by conventional radioisotope-labeled albumin or red blood cell assays, although these 
techniques are relatively impractical in routine clinical practice. The concordance between estimated and measured PV 
is still a matter of debate. Adequation for ePVS in the specific context of HF, especially in patients with large 
variations in body weight, should be further studied. In addition, Patients did not undergo catherization with a high-
fidelity micromanometer-tip catheter. Third, ambulatory patients were recruited in this study and consequently 
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experienced less severe degrees of congestion than patients typically included in acute HF registries: Our results are 
thus only relevant for these lower risk patients. 
Lastly, the sex-specific association identified herein could also be a chance finding. Further investigations are 
needed to determine whether a reproducible sex-specific pattern is observed for the association between ePVS and 
other congestion markers. 
 
Conclusion 
ePVS is associated with E/e’ regardless of sex difference and is associated with invasively-measured LV filling 
pressure only in females. These results suggest that ePVS may be a marker of left-sided hemodynamic congestion 
rather than pulmonary interstitial edema or systemic congestion. 
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Table 1. Patient Characteristics according to Sex-specific Tertiles of Estimated Plasma Volume Status 
* Sex-specific tertiles indicate the tertiles derived from males and females separately.  
M, male; F, female; COPD, chronic obstructive pulmonary disease; ACEi, angiotensin converting enzyme inhibitor; ARB, 
angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; BP, blood 
pressure; eGFR, estimated glomerular filtration rate; NT proBNP, N-terminal prohormone brain natriuretic peptide; ePVS, 
estimated plasma volume status; LVSV, left ventricular systolic volume; LAV, left atrial volume; LVEF, left ventricular ejection 
fraction; E/A, ratio of peak early and late diastolic velocities; e’, mean value of early diastolic velocity at the septal and lateral 
sites of the mitral annulus; E/e’, ratio of early mitral inflow velocity and mitral annular early diastolic velocity; RAV, right atrial 
volume; TAPSE, tricuspid annular plane systolic excursion; IVA, isovolumic acceleration; IVC, inferior vena cava; PASP, 
pulmonary artery systolic pressure; LVEDP, left ventricular end-diastolic pressure.  
 
 
Table 2. Multivariable Model for the Association of Clinical, Biological and Hemodynamic Parameters with 
Estimated Plasma Volume Status 
 
NYHA, New York Heart Association; BP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; NT proBNP, N-
terminal prohormone brain natriuretic peptide; LVSV, left ventricular stroke volume; LAV, left atrial volume; E/A, ratio of peak 
early and late diastolic velocities; E/e’, ratio of early mitral inflow velocity and mitral annular early diastolic velocity; RAV, right 
atrial volume; TAPSE, tricuspid annular plane systolic excursion; IVA, isovolumic acceleration; IVC, inferior vena cava; PASP, 
pulmonary artery systolic pressure; LVEDP, left ventricular end-diastolic pressure. 
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Table 1. Patient Characteristics according to Sex-specific Tertiles of Estimated Plasma Volume Status 
 Global Low Intermediate High p-
value 
p-Value  
1 vs. 3 
p-Value 
2 vs. 3  (N=78) 
M, <3.8 ml/g; 
F, <4.4 ml/g 
(N=26) 
M, 3.8-4.5 ml/g; 
F, 4.4-5.0 ml/g 
(N=26) 
M, >4.5 ml/g; 
F, >5.0 ml/g 
(N=26) 
Age, yrs 74.5 (67.0 - 80.0) 
73.5 
(64.0 - 78.0) 
71.5 
(67.0 - 78.0) 
77.5 
(70.0 - 82.0) 0.15 0.11 0.08 
Males, N (%) 54 (69.2 %) 18 (69.2 %) 18 (69.2 %) 18 (69.2 %) NA NA NA 
Body mass index, kg/m² 25.7 (22.9 - 29.5) 
27.9 
(24.7 - 32.6) 
25.9 
(23.3 - 28.9) 
23.6 
(20.7 - 26.7) <0.01 <0.01 0.12 
Medical history, N (%)        
  Hypertension 53 (67.9 %) 16 (61.5 %) 18 (69.2 %) 19 (73.1 %) 0.66 0.38 0.76 
  Dyslipidemia 35 (44.9 %) 12 (46.2 %) 10 (38.5 %) 13 (50.0 %) 0.70 0.78 0.4 
  Diabetes mellitus 16 (20.5 %) 2 (7.7 %) 7 (26.9 %) 7 (26.9 %) 0.14 0.08 0.99 
  Coronary artery disease 38 (48.7 %) 9 (34.6 %) 12 (46.2 %) 17 (65.4 %) 0.08 0.03 0.17 
  Heart failure 38 (48.7 %) 8 (30.8 %) 13 (50.0 %) 17 (65.4 %) 0.04 0.01 0.26 
  Atrial fibrillation 23 (29.5 %) 10 (38.5 %) 7 (26.9 %) 6 (23.1 %) 0.45 0.23 0.75 
  COPD 6 (7.7 %) 2 (7.7 %) 4 (15.4 %) 0 (0 %) 0.11 0.99 0.99 
  Smoking 30 (38.5 %) 10 (38.5%) 12 (46.2 %) 8 (30.8 %) 0.52 0.56 0.26 
Medications, N (%)        
  ACEi/ARB 48 (61.5 %) 15 (57.7 %) 16 (61.5 %) 17 (65.4 %) 0.85 0.57 0.77 
  Calcium channel blocker 4 (5.1 %) 1 (3.8 %) 1 (3.8 %) 2 (7.7 %) 0.77 0.56 0.56 
  Beta-blocker 44 (56.4 %) 17 (65.4 %) 13 (50.0 %) 14 (53.8 %) 0.51 0.40 0.78 
  MRA 8 (10.3 %) 2 (7.7 %) 2 (7.7 %) 4 (15.4 %) 0.57 0.39 0.39 
Clinical profile        
  NYHA III+IV, N (%) 21 (26.9 %) 6 (23.1 %) 8 (30.8 %) 7 (26.9 %) 0.82 0.75 0.76 
  Systolic BP, mmHg 134.0 (118.0 - 148.0) 
139.0 
(130.0 - 144.0) 
133.0 
(119.0 - 148.0) 
130.0 
(110.0 - 147.0) 0.48 0.27 0.64 
  Diastolic BP, mmHg 72.5 (65.0 - 84.0) 
76.0 
(68.0 - 90.0) 
75.0 
(67.0 - 81.0) 
67.0 
(65.0 - 80.0) 0.17 0.06 0.20 
  Heart rate, bpm 70.5 (61.0 - 83.0) 
70.0 
(61.0 - 86.0) 
76.5 
(59.0 - 83.0) 
67.0 
(62.0 - 75.0) 0.69 0.82 0.35 
Laboratory measurements        
  Hemoglobin, g/dl 13.6 (12.5 - 14.7) 
15.0 
(14.3 - 15.4) 
13.9 
(13.3 - 14.3) 
11.9 
(10.9 - 12.5) <0.01 <0.01 <0.01 
  Sodium, mmol/l 140.0 (137.0 - 141.0) 
140.0 
(138.0 - 141.0) 
140.0 
(138.0 - 142.0) 
138.0 
(137.0 - 141.0) 0.22 0.18 0.12 
  eGFR, ml/min/1.73m² 70.0 (53.0 - 85.0) 
67.1 
(57.2 - 88.0) 
75.3 
(48.0 - 85.0) 
71.0 
(49.0 - 81.0) 0.66 0.44 0.53 
  NT proBNP, pg/ml 1025 (283 - 2384) 
668 
(112 - 2168) 
576 
(172 - 1472) 
2327 
(1025 - 5752) 0.03 0.04 0.01 
  ePVS, ml/g 4.4 (3.8 - 5.0) 
3.7 
(3.5 - 3.8) 
4.2 
(4.0 - 4.5) 
5.4 
(5.0 - 6.1) <0.01 <0.01 <0.01 
LV function        
  LVSV index, ml/m² 31.4 (19.3 - 50.6) 
29.6 
(18.3 - 42.7) 
34.8 
(23.2 - 59.1) 
42.7 
(20.9 - 69.2) 0.18 0.08 0.99 
  LAV index, ml/m² 47.7 (33.4 - 62.3) 
47.3 
(31.8 - 58.9) 
41.9 
(33.3 - 52.3) 
55.4 
(44.4 - 65.5) 0.046 0.06 0.02 
  LVEF, % 52.0 (33.0 - 62.0) 
54.0 
(43.0 - 63.0) 
50.5 
(31.0 - 58.0) 
50.4 
(31.0 - 62.0) 0.25 0.25 0.76 
  LVEF<40%, N (%) 26 (33.3 %) 4 (15.4 %) 10 (38.5 %) 12 (46.2 %) 0.049 0.02 0.58 
  LVEF≥50%, N (%) 42 (53.8 %) 16 (61.5 %) 13 (50.0 %) 13 (50.0 %) 0.63 0.40 1.00 
  Global longitudinal strain, % -12.9 (-18.4 - -8.6) 
-15.2 
(-19.0 - -10.0) 
-13.2 
(-19.4 - -8.6) 
-10.2 
(-16.9 - -7.4) 0.24 0.08 0.40 
  E/A ratio (N=61) 0.9 (0.7 - 1.6) 
0.9 
(0.6 - 1.6) 
0.9 
(0.7 - 1.5) 
1.1 
(0.7 - 1.8) 0.58 0.49 0.90 
  e' mean, cm/s 6.5 (4.5 - 8.5) 
6.8 
(5.5 - 10.0) 
6.5 
(5.0 - 9.0) 
6.0 
(3.5 - 7.0) 0.11 0.04 0.14 
  E/e' mean 12.5 (9.3 - 18.3) 
10.9 
(8.5 - 15.0) 
11.7 
(8.6 - 15.6) 
16.3 
(11.6 - 22.6) 0.02 0.01 0.03 
RV function        
  RAV index, ml/m² 25.4 (19.5 - 34.4) 
29.4 
(19.4 - 44.8) 
22.8 
(19.5 - 28.8) 
26.3 
(19.5 - 34.4) 0.27 0.29 0.52 
  TAPSE, mm 22.8 (18.0 - 25.3) 
23.0 
(19.0 - 26.0) 
24.0 
(20.0 - 30.0) 
20.5 
(18.0 - 24.0) 0.12 0.16 0.047 
  RV IVA, m/sec 1.4 (0.9 - 2.1) 
1.3 
(0.9 - 1.6) 
1.9 
(1.4 - 2.3) 
1.1 
(0.8 - 1.9) 0.03 0.71 0.03 
  IVC dimension, mm 13.0 (8.0 - 16.7) 
13.0 
(6.0 - 16.0) 
12.0 
(7.5 - 16.0) 
13.5 
(10.0 - 20.5) 0.29 0.20 0.15 
  estimated PAPS, mmHg 34.0 (26.0 - 45.0) 
34.0 
(26.0 - 38.0) 
30.0 
(25.0 - 42.0) 
35.0 
(26.0 - 50.0) 0.38 0.21 0.28 
Other parameters        
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  LVEDP, mmHg 16.0 (12.0 - 22.0) 
15.5 
(11.0 - 20.0) 
16.0 
(13.0 - 21.0) 
17.0 
(12.0 - 23.0) 0.77 0.52 0.79 
  LV-PreA, mmHg (N=61) 10.0 (7.0 - 16.0) 
10.0 
(5.0 - 12.0) 
10.0 
(6.5 - 16.0) 
12.0 
(8.0 - 16.0) 0.33 0.15 0.54 
  Total B-Lines 3.0 (0.0 - 12.0) 
2.5 
(0.0 - 12.0) 
1.0 
(0.0 - 9.0) 
4.0 
(0.0 - 19.0) 0.52 0.46 0.29 
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Table 2. Multivariable Model for the Association of Clinical, Biological and Hemodynamic Parameters with 
Estimated Plasma Volume Status 
 Univariable model Multivariable model 
Variables β (95%CI) p-Value β (95%CI) p-Value 
Clinical parameters        Age, yrs (per 5 yrs) 0.15 (0.04 - 0.26) 0.01 — — 
   Male sex -0.54 (-0.99 - -0.08) 0.02 -0.67 (-1.25 - 0.08) 0.03 
   Body mass index, kg/m² (per 5 kg/m²) -0.20 (-0.39 - -0.01) 0.04 — — 
   Hypertension 0.16 (-0.31 - 0.62) 0.50      Diabetes mellitus 0.44 (-0.09 - 0.97) 0.09 — — 
   Coronary artery disease 0.27 (-0.16 - 0.70) 0.21      Heart failure 0.52 (0.10 - 0.94) 0.02 — — 
   NYHA III+IV 0.41 (-0.07 - 0.89) 0.09 — — 
   Diastolic BP, mmHg (per 5 mmHg) -0.13 (-0.21 - -0.05) <0.001 -0.22 (-0.41 - -0.02) 0.03 
Biological parameters        Sodium, mmol/l (per 5 mmol/l) -0.14 (-0.44 - 0.16) 0.35      eGFR, ml/min/1.73m² (per 5 ml/min/1.73m²) -0.03 (-0.08 - 0.03) 0.34      Log NT proBNP 0.24 (0.04 - 0.43) 0.02 — — 
Left ventricular function        LVSV index, ml/m² (per 5 ml/m²) 0.02 (-0.02 - 0.05) 0.43      LAV index, ml/m² (per 5 ml/m²) 0.05 (0.01 - 0.10) 0.03 — — 
   LV ejection fraction, % (per 5%) -0.02 (-0.09 - 0.04) 0.46      LV ejection fraction <40% 0.42 (-0.03 - 0.87) 0.07 — — 
   Global longitudinal strain, % 0.02 (-0.02 - 0.06) 0.24      E/A ratio 0.02 (-0.25 - 0.28) 0.91      E/e' mean 0.04 (0.01 - 0.06) <0.001 0.03 (0.01 - 0.06) 0.03 
Right ventricular function        TAPSE, mm -0.02 (-0.06 - 0.02) 0.27      RV IVA, m/sec -0.09 (-0.29 – 0.12) 0.40      IVC dimension, mm 0.01 (-0.03 - 0.05) 0.51      estimated PAPS, mmHg (per 5 mmHg) 0.06 (-0.02 - 0.13) 0.15   Other parameters        LVEDP, mmHg 0.01 (-0.02 - 0.04) 0.37      Total B-Lines 0.02 (-0.01 - 0.04) 0.18   
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Graphic abstract 
 
Figure 1. Scatterplots of Congestion Markers with Estimated Plasma Volume Status according to Sex 
Difference 
 
ePVS, estimated plasma volume status; NT proBNP, N-terminal prohormone brain natriuretic peptide; E/e’, ratio of early mitral 
inflow velocity and mitral annular early diastolic velocity; LAV, left atrial volume; IVC, inferior vena cava; LVEDP, left 
ventricular end-diastolic pressure 
 
Central Illustration. Association between Congestion Markers and Estimated Plasma Volume Status 
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Figure 1. Scatterplots of Congestion Markers with Estimated Plasma Volume Status according to Sex Difference 
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Central Illustration. Association between Congestion Markers and Estimated Plasma Volume Status 
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Supplementary table 1. Correlation Matrix between Estimated Plasma Volume Status and Congestion 
Markers across Heart Rhythm and Left Ventricular Ejection Fraction Strata 
 
Sinus rhythm 
(N=61) 
Atrial fibrillation 
(N=17) p-value for 
interaction 
LVEF≥50% 
(N=42) 
LVEF<50% 
(N=36) p-value for 
interaction 
 rho p-value rho p-value rho p-value rho p-value 
Log NTproBNP 0.49 0.002 0.26 0.43 0.93 0.47 0.01 0.44 0.06 0.57 
E/e’ mean 0.39 0.002 0.06 0.82 0.02 0.33 0.03 0.31 0.06 0.30 
LAV index 0.31 0.01 0.36 0.16 0.84 0.25 0.11 0.34 0.04 0.34 
IVC dimension 0.11 0.41 0.19 0.48 0.60 -0.06 0.72 0.25 0.14 0.84 
LVEDP 0.08 0.56 0.14 0.60 0.91 0.14 0.38 0.04 0.81 0.73 
Total B-lines 0.13 0.30 -0.13 0.62 0.60 0.07 0.67 0.12 0.49 0.86 
Correlations were analyzed using Spearman’s correlation.  
NT proBNP, N-terminal prohormone brain natriuretic peptide; E/e’, ratio of early mitral inflow velocity and mitral annular early 
diastolic velocity; LAV, left atrial volume; IVC, inferior vena cava; LVEDP, left ventricular end-diastolic pressure.
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Supplementary table 2. Patient Characteristics according to Sex-specific Tertiles of Estimated Plasma 
Volume Status (Hakim formula) 
  Sex specific ePVS tertiles  
 
Global Low Intermediate High 
p-value (N=78) 
M, <-12.9%; 
F, <-9.7% 
(N=26) 
M, -12.9 - -3.4%; 
F, -9.7 – 0.2% 
(N=26) 
M, -3.4%>; 
F, 0.2%> 
(N=26) 
Age, yrs 74.5 (67.0 - 80.0) 
71.5 
(64.0 - 76.0) 
75.0 
(67.0 - 79.0) 
78.0 
(70.0 - 83.0) 0.02 
Males, N (%) 54 (69.2 %) 18 (69.2 %) 18 (69.2 %) 18 (69.2 %) NA 
Body mass index, kg/m² 25.7 (22.9 - 29.5) 
29.8 
(25.9 - 32.7) 
25.3 
(22.9 - 28.7) 
23.1 
(20.7 - 25.2) <0.001 
Medical history, N (%)         Hypertension 53 (67.9 %) 18 (69.2 %) 17 (65.4 %) 18 (69.2 %) 0.94 
   Dyslipidemia 35 (44.9 %) 10 (38.5 %) 13 (50.0 %) 12 (46.2 %) 0.70 
   Diabetes mellitus 16 (20.5 %) 2 (7.7 %) 9 (34.6 %) 5 (19.2 %) 0.06 
   Coronary artery disease 38 (48.7 %) 8 (30.8 %) 14 (53.8 %) 16 (61.5 %) 0.07 
   Heart failure 38 (48.7 %) 11 (42.3 %) 11 (42.3 %) 16 (61.5 %) 0.28 
   Atrial fibrillation 23 (29.5 %) 12 (46.2 %) 4 (15.4 %) 7 (26.9 %) 0.048 
   COPD 6 (7.7 %) 3 (11.5 %) 3 (11.5 %) 0 (0 %) 0.20 
   Smoking 30 (38.5 %) 9 (34.6 %) 12 (46.2 %) 9 (34.6 %) 0.61 
Medications, N (%)         ACEi/ARB 48 (61.5 %) 15 (57.7 %) 17 (65.4 %) 16 (61.5 %) 0.85 
  Calcium channel blockers 4 (5.1 %) 1 (3.8 %) 1 (3.8 %) 2 (7.7 %) 0.77 
   Beta-blocker 44 (56.4 %) 17 (65.4 %) 11 (42.3 %) 16 (61.5 %) 0.20 
   MRA 8 (10.3 %) 2 (7.7 %) 4 (15.4 %) 2 (7.7 %) 0.57 
Clinical profile         NYHA III+IV, N (%) 21 (26.9 %) 7 (26.9 %) 8 (30.8 %) 6 (23.1 %) 0.82 
   Systolic BP, mmHg 134.0 (118.0 - 148.0) 
138.0 
(130.0 - 145.0) 
133.0 
(119.0 - 153.0) 
132.0 
(110.0 - 147.0) 0.55 
   Diastolic BP, mmHg 72.5 (65.0 - 84.0) 
76.0 
(65.0 - 90.0) 
75.0 
(67.0 - 80.0) 
70.0 
(65.0 - 80.0) 0.24 
   Heart rate, bpm 70.5 (61.0 - 83.0) 
75.0 
(64.0 - 90.0) 
72.5 
(60.0 - 83.0) 
66.0 
(60.0 - 75.0) 0.36 
Laboratory measurements      
   Hemoglobin, g/dl 13.6 (12.5 - 14.7) 
14.8 
(14.0 - 15.4) 
13.8 
(12.8 - 14.6) 
12.2 
(10.9 - 12.7) <0.001 
   Sodium, mmol/l 140.0 (137.0 - 141.0) 
140.0 
(137.0 - 141.0) 
140.0 
(138.0 - 141.0) 
138.5 
(137.0 - 141.0) 0.37 
   eGFR, ml/min/1.73m² 70.0 (53.0 - 85.0) 
68.5 
(56.0 - 91.1) 
66.1 
(49.0 - 84.4) 
72.2 
(52.0 - 81.0) 0.60 
   NT proBNP, pg/ml 1025 (283 - 2384) 
661 
(113 - 2384) 
595 
(204 - 2074) 
1777 
(1025 - 3738) 0.10 
   ePVS, % -20.6 (-29.9 - -9.7) 
-33.0 
(-37.7 - -16.6) 
-26.9 
(-28.4 - -8.7) 
-12.8 
(-16.8 - 4.0) <0.001 
LV function      
   LVSV index, ml/m² 31.4 (19.3 - 50.6) 
30.3 
(19.5 - 47.8) 
31.6 
(18.8 - 48.8) 
35.7 
(20.9 - 69.2) 0.67 
   LAV index, ml/m² 47.7 (33.4 - 62.3) 
44.2 
(28.5 - 52.4) 
48.9 
(33.8 - 62.3) 
53.3 
(36.6 - 65.5) 0.06 
   LVEF, % 52.0 (33.0 - 62.0) 
48.0 
(40.0 - 62.0) 
53.3 
(37.0 - 61.4) 
50.4 
(31.0 - 62.0) 0.78 
   LVEF<40%, N (%) 26 (33.3 %) 6 (23.1 %) 8 (30.8 %) 12 (46.2 %) 0.20 
   LVEF≥50%, N (%) 42 (53.8 %) 12 (46.2 %) 17 (65.4 %) 13 (50.0 %) 0.34 
   Global longitudinal strain, % -12.9 (-18.4 - -8.6) 
-13.6 
(-18.0 - -8.6) 
-15.2 
(-19.2 - -9.8) 
-10.3 
(-16.9 - -7.4) 0.28 
   E/A ratio (N=61) 0.9 (0.7 - 1.6) 
0.9 
(0.6 - 1.5) 
0.9 
(0.7 - 1.9) 
1.0 
(0.8 - 1.8) 0.60 
   e' mean, cm/s 6.5 (4.5 - 8.5) 
6.8 
(5.0 - 9.5) 
6.5 
(5.0 - 9.0) 
6.5 
(3.5 - 7.0) 0.36 
   E/e' mean 12.5 (9.3 - 18.3) 
10.4 
(8.4 - 14.7) 
13.1 
(9.4 - 18.5) 
15.5 
(11.1 - 22.6) 0.054 
RV function      
   RAV index, ml/m² 25.4 (19.5 - 34.4) 
27.6 
(19.6 - 34.1) 
24.8 
(19.3 - 35.6) 
25.6 
(19.5 - 31.2) 0.77 
   TAPSE, mm 22.8 (18.0 - 25.3) 
22.5 
(19.0 - 25.0) 
23.5 
(18.0 - 30.0) 
21.5 
(18.0 - 24.0) 0.24 
   RV IVA, m/sec 1.4 (0.9 - 2.1) 
1.4 
(0.9 - 1.7) 
1.7 
(1.1 - 2.2) 
1.2 
(0.8 - 2.1) 0.16 
   IVC dimension, mm 13.0 12.0 14.5 12.5 0.54 
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(8.0 - 16.7) (6.0 - 16.7) (9.0 - 16.0) (9.5 - 20.0) 
   estimated PAPS, mmHg 34.0 (26.0 - 45.0) 
34.0 
(23.0 - 40.0) 
30.0 
(27.0 - 45.0) 
35.0 
(26.0 - 50.0) 0.38 
Other parameters      
   LVEDP, mmHg 16.0 (12.0 - 22.0) 
14.5 
(10.0 - 20.0) 
16.0 
(14.0 - 21.0) 
17.0 
(12.0 - 23.0) 0.40 
   LV-PreA, mmHg (N=61) 10.0 (7.0 - 16.0) 
8.5 
(5.0 - 10.0) 
12.0 
(8.0 - 17.0) 
11.0 
(8.0 - 16.0) 0.08 
   Total B-Lines 3.0 (0.0 - 12.0) 
2.0 
(0.0 - 9.0) 
4.5 
(0.0 - 12.0) 
4.0 
(0.0 - 19.0) 0.80 
* Sex specific tertiles indicate the tertiles derived from male and female separately.  
M, male; F, female; COPD, chronic obstructive pulmonary disease; ACEi, angiotensin converting enzyme inhibitor; ARB, 
angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; BP, blood 
pressure; eGFR, estimated glomerular filtration rate; NT proBNP, N-terminal prohormone brain natriuretic peptide; ePVS, 
estimated plasma volume status; LVSV, left ventricular systolic volume; LAV, left atrial volume; LVEF, left ventricular ejection 
fraction; E/A, ratio of peak early and late diastolic velocities; e’, mean value of early diastolic velocity at the septal and lateral 
sites of the mitral annulus; E/e’, ratio of early mitral inflow velocity and mitral annular early diastolic velocity; RAV, right atrial 
volume; TAPSE, tricuspid annular plane systolic excursion; IVA, isovolumic acceleration; IVC, inferior vena cava; PASP, 
pulmonary artery systolic pressure; LVEDP, left ventricular end-diastolic pressure. 
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Supplementary table 3. Multivariable Model for the Association of Clinical, Biological and 
Hemodynamic Parameters with Estimated Plasma Volume Status (Hakim formula) 
 Univariable model Multivariable model 
 β (95%CI) p-Value β (95%CI) p-Value 
Clinical parameters     
   Age, yrs (per 5 yrs) 1.81 (0.59 - 3.03) 0.004 ― ― 
   Male sex -3.01 (-8.21 - 2.20) 0.25   
   Body mass index, kg/m² (per 5 kg/m²) -6.07 (-7.75 - -4.38) <0.001 -6.07 (-8.26 - -3.89) <0.001 
   Hypertension -0.34 (-5.54 - 4.85) 0.90   
   Diabetes mellitus 0.90 (-5.10 - 6.90) 0.77   
   Coronary artery disease 2.41 (-2.41 - 7.23) 0.32   
   Heart failure 4.19 (-0.57 – 8.94) 0.08 ― ― 
   NYHA III+IV 1.26 (-4.19 - 6.72) 0.65   
   Diastolic BP, mmHg (per 5 mmHg) -1.84 (-3.63 - -0.06) 0.043 -2.45 (-4.22 - -0.68) 0.008 
Biological parameters     
   Sodium, mmol/l (per 5 mmol/l) -1.88 (-5.20 - 1.45) 0.26   
   eGFR, ml/min/1.73m² (per 5 ml/min/1.73m²) -0.16 (-0.75 - 0.43) 0.59   
   Log NT proBNP 1.91 (-0.13 - 3.95) 0.07 ― ― 
Left ventricular function     
   LVSV index, ml/m² (per 5 ml/m²) 0.27 (-0.14 - 0.68) 0.20   
   LAV index, ml/m² (per 5 ml/m²) 0.75 (0.24 - 1.26) 0.005 ― ― 
   LV ejection fraction, % (per 5%) -0.10 (-0.84 - 0.63) 0.78   
   LV ejection fraction <40% 4.15 (-0.90 – 9.20) 0.11   
   Global longitudinal strain, % 0.22 (-0.21 - 0.65) 0.31   
   E/A ratio -0.02 (-2.88 - 2.85) 0.99   
   E/e' mean 0.32 (0.06 - 0.59) 0.02 ― ― 
Right ventricular function     
   TAPSE, mm -0.25 (-0.68 - 0.18) 0.25   
   RV IVA, m/sec -0.11 (-2.37 - 2.16) 0.93   
   IVC dimension, mm 0.10 (-0.32 - 0.52) 0.64   
   estimated PAPS, mmHg (per 5 mmHg) 0.59 (-0.29 - 1.47) 0.18   
Others     
   LVEDP, mmHg 0.05 (-0.27 - 0.37) 0.75   
   Total B-Lines 0.15 (-0.10 - 0.39) 0.24   NYHA, New York Heart Association; BP, diastolic blood pressure; eGFR, eGFR, estimated glomerular filtration rate; NT 
proBNP, N-terminal prohormone brain natriuretic peptide; LVSV, left ventricular stroke volume; LAV, left atrial volume; E/A 
ratio of peak early and late diastolic velocities; E/e’, ratio of early mitral inflow velocity and mitral annular early diastolic 
velocity; RAV, right atrial volume; TAPSE, tricuspid annular plane systolic excursion; IVA, isovolumic acceleration; IVC, 
inferior vena cava; PASP, pulmonary artery systolic pressure; LVEDP, left ventricular end-diastolic pressure.  
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